Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego, California, and in Shanghai and Yangzhou, China, has reportedly secured over RMB 100 million in a strategic financing round. The funding was led by Yangzhou Guojin, Longchuan Holding, and other municipal state-owned funds based in Yangzhou. The capital raised is intended to bolster the company’s technology research and development, as well as regulatory filing, manufacturing, and commercialization efforts.
Established in 2014, Singlera Genomics possesses proprietary technologies in single-cell sequencing, DNA methylation, and bioinformatics. The company offers leading products and services, including tumor diagnosis and non-invasive prenatal diagnosis, covering a spectrum of cancers such as lung, colorectal, liver, stomach, esophageal, pancreatic, and thyroid. In May this year, Singlera received approval in China for its Septin9, BCAT1, IKZF1, BCAN, VAV3 gene methylation combined detection kit, which uses the PCR fluorescence probe method. This follows the breakthrough therapy designation (BTD) granted in the U.S. in May last year for PDACatch, an early detection technique for pancreatic cancer.- Flcube.com
